Her-2 in gastroesophageal cancer: Pathobiology, diagnostic and therapeutic implications

European Surgery - Acta Chirurgica Austriaca

Volumn 43, Issue 3, 2011, Pages 162-167

  Birner, P ^a   Schoppmann, S F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gastroesophageal cancer; Her 2; Heterogeneity; Targeted therapy

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; LAPATINIB; PERTUZUMAB; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DNA HYBRIDIZATION; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE FUNCTION; GENE OVEREXPRESSION; HEART FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PROTEIN FUNCTION; RASH; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; SYSTOLIC DYSFUNCTION;

EID: 80052565515     PISSN: 16828631     EISSN: 16824016     Source Type: Journal    
DOI: 10.1007/s10353-011-0619-5     Document Type: Review

References (68)

1. DM Parkin P Pisani J Ferlay 1999 Estimates of the worldwide incidence of 25 major cancers in 1990 Int J Cancer 80 827 841 10074914 10.1002/(SICI)1097- 0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P 1:STN:280:DyaK1M7ntlajuw%3D%3D (Pubitemid 29108856)
2. KD Crew AI Neugut 2004 Epidemiology of upper gastrointestinal malignancies Semin Oncol 31 450 464 15297938 10.1053/j.seminoncol.2004.04.021 (Pubitemid 39070265)
3. AJ Graham FM Shrive WA Ghali, et al. 2007 Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis Ann Thorac Surg 83 1257 1264 17383322 10.1016/j.athoracsur.2006.11.061 (Pubitemid 46440778)
4. T Ng T Dipetrillo J Purviance, et al. 2006 Multimodality treatment of esophageal cancer: a review of the current status and future directions Curr Oncol Rep 8 174 182 16618381 10.1007/s11912-006-0017-5 1:CAS:528: DC%2BD28XkslKrtL8%3D
5. Y Kodera M Fujiwara N Ohashi, et al. 2010 Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials J Am Coll Surg 211 677 686 20869270 10.1016/j.jamcollsurg.2010.07.013
6. SR Lord PS Hall P McShane, et al. 2010 Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy Clin Oncol (R Coll Radiol) 22 107 113 1:STN:280: DC%2BC3c7jtVyhtQ%3D%3D
7. J Meza-Junco HJ Au MB Sawyer 2009 Trastuzumab for gastric cancer Expert Opin Biol Ther 9 1543 1551 19916733 10.1517/14712590903439702 1:CAS:528:DC%2BD1MXhsVClu7rK
8. D Cunningham WH Allum SP Stenning, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20 16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
9. A Bamias ME Hill D Cunningham, et al. 1996 Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival Cancer 77 1978 1985 8640659 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D 1:CAS:528:DyaK28XjtFGrsLs%3D (Pubitemid 26142038)
10. L Coussens TL Yang-Feng YC Liao, et al. 1985 Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1132 1139 2999974 10.1126/science.2999974 1:CAS:528:DyaL28XmslKhuw%3D%3D (Pubitemid 16169997)
11. D Graus-Porta RR Beerli JM Daly, et al. 1997 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1647 1655 9130710 10.1093/emboj/16.7.1647 1:CAS:528:DyaK2sXislKltLo%3D (Pubitemid 27151960)
12. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
13. CC Benz GK Scott JC Sarup, et al. 1992 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 85 95 8095168 10.1007/BF01961241 1:STN:280: DyaK3s7osVentQ%3D%3D (Pubitemid 23063891)
14. SF Schoppmann D Tamandl L Roberts, et al. 2010 HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer Ann Oncol 21 955 960 19940005 10.1093/annonc/mdp532 1:STN:280:DC%2BC3c3ptF2lsA%3D%3D
15. TA Christianson JK Doherty YJ Lin, et al. 1998 NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res 58 5123 5129 9823322 1:CAS:528:DyaK1cXnsFSmtL4%3D (Pubitemid 28521172)
16. R Colomer S Montero A Lluch, et al. 2000 Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer Clin Cancer Res 6 2356 2362 10873087 1:CAS:528:DC%2BD3cXksVGhsL8%3D (Pubitemid 30399203)
17. RS Finn R Gagnon A Di Leo, et al. 2009 Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study J Clin Oncol 27 5552 5558 19858400 10.1200/JCO.2008.21.1763 1:CAS:528:DC%2BC3cXhtVWit70%3D
18. S Scholl P Beuzeboc P Pouillart 2001 Targeting HER2 in other tumor types Ann Oncol 12 Suppl 1 S81 S87 11521727 10.1023/A:1011192622688
19. H Grabsch S Sivakumar S Gray, et al. 2010 HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series Cell Oncol 32 57 65 20208134
20. E Rossi V Villanacci G Bassotti, et al. 2006 Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization Diagn Mol Pathol 15 125 130 16932066 10.1097/01.pdm.0000213455.22527.f7 1:CAS:528:DC%2BD28XhtVWnt7zP (Pubitemid 44325472)
21. JS Ross EA Slodkowska WF Symmans, et al. 2009 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320 368 19346299 10.1634/theoncologist.2008-0230 1:CAS:528:DC%2BD1MXlvFOhtLw%3D
22. D Gancberg A Di Leo F Cardoso, et al. 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 1036 1043 12176781 10.1093/annonc/mdf252 1:STN:280: DC%2BD38vitFWgtQ%3D%3D
23. V Guarneri S Giovannelli G Ficarra, et al. 2008 Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 838 844 18650259 10.1634/theoncologist.2008-0048 1:CAS:528:DC%2BD1cXhtF2qs7vP
24. U Reichelt P Duesedau M Tsourlakis, et al. 2007 Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus Mod Pathol 20 120 129 17143264 10.1038/modpathol.3800712 1:CAS:528: DC%2BD28XhtlaktrnL (Pubitemid 44967957)
25. AH Marx L Tharun J Muth, et al. 2009 HER-2 amplification is highly homogenous in gastric cancer Hum Pathol 40 769 777 19269014 10.1016/j.humpath. 2008.11.014 1:CAS:528:DC%2BD1MXmtFektb8%3D
26. Schoppmann SF, Jesch B, Zacherl J, et al. Her-2 status in primary oesophageal cancer and corresponding lymph-node and distant metastases. Br J Surg 2011; (in press)
27. P Birner G Oberhuber J Stani, et al. 2001 Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 1669 1675 11410505 1:STN:280:DC%2BD3MzkslagtA%3D%3D (Pubitemid 32708634)
28. YJ Bang E Van Cutsem A Feyereislova, et al. 2010 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687 697 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO
29. P Birner G Oberhuber 2002 Is fluorescence in situ hybridization really superior to HercepTest? J Clin Oncol 20 4607 12454125 10.1200/JCO.2002.99.178 author reply 4607-9 (Pubitemid 35402971)
30. M Hofmann O Stoss T Gaiser, et al. 2008 Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J Clin Pathol 61 89 94 17412870 10.1136/jcp.2006.043562 1:CAS:528:DC%2BD1cXitlWlsbg%3D (Pubitemid 351158232)
31. M Hofmann O Stoss D Shi, et al. 2008 Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 797 805 18422971 10.1111/j.1365-2559.2008.03028.x 1:STN:280:DC%2BD1czjtFWlsA%3D%3D (Pubitemid 351724903)
32. J Baselga L Norton J Albanell, et al. 1998 Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res 58 2825 2831 9661897 1:CAS:528:DyaK1cXksFCqt7g%3D (Pubitemid 28311914)
33. J Albanell J Codony A Rovira, et al. 2003 Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 Adv Exp Med Biol 532 253 268 12908564 10.1007/978-1-4615-0081-0-21 1:CAS:528:DC%2BD3sXot1Ggsbc%3D (Pubitemid 37176793)
34. XF Le F Pruefer RC Bast Jr 2005 HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways Cell Cycle 4 87 95 15611642 10.4161/cc.4.1.1360 1:CAS:528:DC%2BD28XjtVertLc%3D (Pubitemid 41038933)
35. MA Molina J Codony-Servat J Albanell, et al. 2001 Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res 61 4744 4749 11406546 1:CAS:528:DC%2BD3MXks1Grtbo%3D (Pubitemid 32691885)
36. DF Hayes MH Picard 2006 Heart of darkness: the downside of trastuzumab J Clin Oncol 24 4056 4058 16908930 10.1200/JCO.2006.07.5143 1:CAS:528: DC%2BD28XhtVantbzL (Pubitemid 46622279)
37. EA Perez R Rodeheffer 2004 Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 322 329 14722042 10.1200/JCO.2004.01.120 1:CAS:528: DC%2BD2cXpsVKitLY%3D (Pubitemid 41095098)
38. E Senkus J Jassem 2010 Cardiovascular effects of systemic cancer treatment Cancer Treat Rev 37 300 21126826 10.1016/j.ctrv.2010.11.001
39. E Tagliabue A Balsari M Campiglio, et al. 2010 HER2 as a target for breast cancer therapy Expert Opin Biol Ther 10 711 724 20214497 10.1517/14712591003689972 1:CAS:528:DC%2BC3cXksFCgtr8%3D
40. MC Franklin KD Carey FF Vajdos, et al. 2004 Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 317 328 15093539 10.1016/S1535-6108(04)00083-2 1:CAS:528:DC%2BD2cXjvVaqtLc%3D (Pubitemid 38482068)
41. P Aggarwal LP Vaites JK Kim, et al. 2010 Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase Cancer Cell 18 329 340 20951943 10.1016/j.ccr.2010.08. 012 1:CAS:528:DC%2BC3cXhtlSnu77K
42. L Bacharova S Hlavacka V Rusnakova 2001 Basic assessment of needs for training in evidence-based medicine in Slovakia Bratisl Lek Listy 102 218 225 11723681 1:STN:280:DC%2BD3Mnnsl2lsg%3D%3D
43. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
44. Y Yonemura I Ninomiya A Yamaguchi, et al. 1991 Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer Cancer Res 51 1034 1038 1670998 1:STN:280:DyaK3M7gsFKqsw%3D%3D
45. M Al-Kasspooles JH Moore MB Orringer, et al. 1993 Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas Int J Cancer 54 213 219 8098013 10.1002/ijc.2910540209 1:STN:280: DyaK3s3lt1CqtA%3D%3D (Pubitemid 23154884)
46. T Nakamura H Nekarda AH Hoelscher, et al. 1994 Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus Cancer 73 1785 1794 7907940 10.1002/1097-0142(19940401)73:7<1785:: AID-CNCR2820730703>3.0.CO;2-0 1:STN:280:DyaK2c7osV2juw%3D%3D (Pubitemid 24101951)
47. JF Flejou F Paraf F Muzeau, et al. 1994 Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations J Clin Pathol 47 23 26 7907608 10.1136/jcp.47.1.23 1:STN:280:DyaK2c7nvFGhsw%3D%3D (Pubitemid 24057743)
48. FG Duhaylongsod MR Gottfried JD Iglehart, et al. 1995 The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus Ann Surg 221 677 683 7794072 10.1097/00000658-199506000-00007 1:STN:280:DyaK2MzhsVCitA%3D%3D discussion 683-74
49. T Ishikawa M Kobayashi M Mai, et al. 1997 Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization Am J Pathol 151 761 768 9284825 1:CAS:528:DyaK2sXmt1Squr8%3D (Pubitemid 27385608)
50. S Gurel E Dolar O Yerci, et al. 1999 The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer J Int Med Res 27 74 78 10446693 1:STN:280:DyaK1MznsFyquw%3D%3D (Pubitemid 29346813)
51. M Nakajima H Sawada Y Yamada, et al. 1999 The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 1894 1902 10223227 1:CAS:528:DyaK1MXjtVCqsro%3D (Pubitemid 29202761)
52. TP Brien RD Odze CE Sheehan, et al. 2000 HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma Hum Pathol 31 35 39 10665910 10.1016/S0046-8177(00)80195-1 1:CAS:528: DC%2BD3cXptVegtA%3D%3D (Pubitemid 30054384)
53. H Allgayer R Babic KU Gruetzner, et al. 2000 c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems J Clin Oncol 18 2201 2209 10829039 1:STN:280:DC%2BD3c3ptFajtw%3D%3D (Pubitemid 30350211)
54. H Geddert M Zeriouh M Wolter, et al. 2002 Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions Am J Clin Pathol 118 60 66 12109857 10.1309/KG1Y-XNGD-54NK-PP66 1:CAS:528: DC%2BD38Xlslyrsrw%3D (Pubitemid 34734253)
55. T Takehana K Kunitomo K Kono, et al. 2002 Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay Int J Cancer 98 833 837 11948459 10.1002/ijc.10257 1:CAS:528:DC%2BD38Xis1Ohtbw%3D (Pubitemid 34286677)
56. J Pinto-de-Sousa L David R Almeida, et al. 2002 c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma Int J Surg Pathol 10 247 256 12490974 10.1177/106689690201000402 1:CAS:528:DC%2BD3sXktVSrtw%3D%3D (Pubitemid 35461524)
57. CT Miller JR Moy L Lin, et al. 2003 Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia Clin Cancer Res 9 4819 4825 14581353 1:CAS:528:DC%2BD3sXosVGjtr0%3D (Pubitemid 37323285)
58. PS Dahlberg BA Jacobson G Dahal, et al. 2004 ERBB2 amplifications in esophageal adenocarcinoma Ann Thorac Surg 78 1790 1800 15511476 10.1016/j.athoracsur.2004.05.037 (Pubitemid 39423556)
59. M Tanner M Hollmen TT Junttila, et al. 2005 Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273 278 15668283 10.1093/annonc/mdi064 1:STN:280:DC%2BD2M%2FjvFyhsg%3D%3D (Pubitemid 40309309)
60. DI Park JW Yun JH Park, et al. 2006 HER-2/neu amplification is an independent prognostic factor in gastric cancer Dig Dis Sci 51 1371 1379 16868827 10.1007/s10620-005-9057-1 1:CAS:528:DC%2BD28Xosleqs7Y%3D (Pubitemid 44315804)
61. T Yano T Doi A Ohtsu, et al. 2006 Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15 65 71 16328035
62. MA Kim EJ Jung HS Lee, et al. 2007 Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction Hum Pathol 38 1386 1393 17555797 10.1016/j.humpath.2007.02.005 1:CAS:528: DC%2BD2sXpt1enur4%3D (Pubitemid 47247482)
63. J Matsubara Y Yamada Y Hirashima, et al. 2008 Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer Clin Cancer Res 14 3022 3029 18483367 10.1158/1078-0432.CCR-07-1898 1:CAS:528:DC%2BD1cXmtVCmtLc%3D
64. JD Barros-Silva D Leitao L Afonso, et al. 2009 Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients Br J Cancer 100 487 493 19156142 10.1038/sj.bjc. 6604885 1:CAS:528:DC%2BD1MXhsFeksbc%3D
65. XL Zhang YS Yang DP Xu, et al. 2009 Comparative study on overexpression of HER2/neu and HER3 in gastric cancer World J Surg 33 2112 2118 19636613 10.1007/s00268-009-0142-z
66. SF Schoppmann B Jesch J Friedrich, et al. 2010 Expression of Her-2 in carcinomas of the esophagus Am J Surg Pathol 34 1868 1873 21107094 10.1097/PAS.0b013e3181f8be17
67. B Yan EX Yau SS Bte Omar, et al. 2010 A study of HER2 gene amplification and protein expression in gastric cancer J Clin Pathol 63 839 842 20696687 10.1136/jcp.2010.076570
68. Thompson SK, Sullivan TR, Davies R, et al. HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011; Jan 26; Epub ahead of print